Segments

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

SEGMENTS

SEGMENTS

We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended June 30,				For the six months ended June 30,
(In thousands)	2022		2021		2022		2021
Revenue from services:
Pharmaceutical	$	—	$	—	$	—	$	—
Diagnostics	186,804		397,197		473,402		904,149
Corporate	—		—		—		—
	$	186,804	$	397,197	$	473,402	$	904,149
Revenue from products:
Pharmaceutical	$	35,892	$	35,663	$	72,550	$	69,608
Diagnostics	—		—		—		—
Corporate	—		—		—		—
	$	35,892	$	35,663	$	72,550	$	69,608
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	87,197	$	9,548	$	93,159	$	13,816
Diagnostics	—		—		—		—
Corporate	—		—		—		—
	$	87,197	$	9,548	$	93,159	$	13,816
Operating income (loss):
Pharmaceutical	$	55,435	$	(13,710)	$	37,327	$	(32,868)
Diagnostics	(57,543)		30,000		(101,092)		97,014
Corporate	(8,631)		(10,719)		(19,399)		(20,138)
	$	(10,739)	$	5,571	$	(83,164)	$	44,008
Depreciation and amortization:
Pharmaceutical	$	17,840	$	7,007	$	33,242	$	14,420
Diagnostics	10,155		13,566		22,567		26,141
Corporate	—		—		—		—
	$	27,995	$	20,573	$	55,809	$	40,561
Loss from investment in investees:
Pharmaceutical	$	(268)	$	(67)	$	(316)	$	(110)
Diagnostics	—		—		—		—
Corporate	—		—		—		—
	$	(268)	$	(67)	$	(316)	$	(110)
Revenues:
United States	$	193,105	$	402,291	$	484,913	$	915,163
Ireland	89,177		12,088		97,638		19,218
Chile	15,804		18,657		32,143		32,809
Spain	5,696		5,437		12,805		11,356
Israel	1,854		724		3,412		3,235
Mexico	4,055		3,039		7,805		5,457
Other	202		172		395		335
	$	309,893	$	442,408	$	639,111	$	987,573

(In thousands)	June 30, 2022		December 31, 2021
Assets:
Pharmaceutical	$	1,354,058	$	1,114,460
Diagnostics	748,165		1,238,583
Corporate	267,379		46,672
	$	2,369,602	$	2,399,715
Goodwill:
Pharmaceutical	$	295,820	$	237,576
Diagnostics	283,025		283,025
	$	578,845	$	520,601

No customer represented more than 10% of our total consolidated revenue during the six months ended June 30, 2022 and 2021. As of June 30, 2022 and December 31, 2021, no customer represented more than 10% of our accounts receivable balance.